MEI Pharma, Inc. - Common Stock (MEIP)

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer (“mCRC”) in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“OXPHOS”), in combination with bevacizumab (Avastin®) had no disease progression at Week 16. This landmark analysis exceeded the 20% threshold set in the Clinical Study Protocol to add an additional 20 patients to the study via the initiation of Cohort 2. The combination was also observed to be generally well-tolerated to date. While the threshold was met to proceed to Cohort 2, it was separately reported today that following a strategic review, the Company decided to continue to advance ME-344 development via its ongoing development of a new formulation rather than through the addition of a new cohort. The Company believes this represents the optimal approach to leveraging the potential of the program. The Company has already initiated research and development activity of the new formulation with encouraging results, with the goal of increasing biological activity, improving convenience of administration and increasing commercial opportunity.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 (“BCL2”) inhibitor, in relapsed and refractory (“R/R”) acute myeloid leukemia (“AML”) patients. The Safety Review Committee recommended initiating the expansion cohort after observing anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell differentiation protein (“Mcl-1”) in available patient samples, no overlapping toxicity or dose limiting toxicities, and favorable safety results to date.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gastrointestinal Cancers Symposium to be held January 18 – 20, 2024.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, alone and in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor, in patients with acute myeloid leukemia (“AML”) or B-cell malignancies, is highlighted in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president and chief executive officer, will present a company overview and business update on Wednesday, November 15 at 8:35 AM Eastern Time.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board of Directors today declared a special cash dividend (the “Dividend”) of $1.75 per share of common stock, $0.00000002 par value, payable on December 6, 2023 to stockholders of record at the close of business on November 17, 2023. The Company expects 100% of the special dividend to be characterized for tax purposes as return of capital to shareholders.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (CDK9) inhibitor, alone and in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor, in patients with acute myeloid leukemia (AML) or B-cell malignancies, will be presented during a poster session at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 9 – 12, 2023.

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announced that they have entered into a cooperation agreement. Key terms of the agreement include:

MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission (“SEC”) on October 17, 2023 in connection with the consent solicitation initiated by Anson Advisors and Cable Car Capital to remove the entire MEI Board of Directors.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”) under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances.

MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC.

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.

MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the close of the U.S. financial markets on September 26, 2023. Company management will host a conference call and webcast that day at 5:00 p.m. ET to discuss the results and provide a corporate overview.